Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Current Deferred Revenue data on record, last reported at $12.5 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 33.24% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $12.5 million, down 33.24%, while the annual FY2025 figure was $12.5 million, 33.24% down from the prior year.
  • Current Deferred Revenue reached $12.5 million in Q4 2025 per CCCC's latest filing, down from $37.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $55.8 million in Q1 2024 and bottomed at $8.4 million in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $27.0 million, with a median of $27.6 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: surged 161.91% in 2024, then plummeted 61.35% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $31.8 million in 2021, then rose by 5.39% to $33.5 million in 2022, then crashed by 53.84% to $15.5 million in 2023, then grew by 20.95% to $18.7 million in 2024, then plummeted by 33.24% to $12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $12.5 million in Q4 2025, $37.0 million in Q3 2025, and $43.8 million in Q2 2025.